QIANJIANG YONGAN PHARMACEUTICAL CO., LTD.

Qianjiang Yongan Pharmaceutical Co., Ltd.

002365

CNE100000LZ9

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 18:00:00 2024-07-16 EDT			5-day change	1st Jan Change
7.04 ^CNY	-0.28%		-0.71%	-28.02%

07-02	Tranche Update on Qianjiang Yongan Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on April 30, 2024.	CI
06-28	Qianjiang Yongan Pharmaceutical Co., Ltd. Approves the Final Cash Dividend on A Shares for the Year 2023, Payable on 05 July 2024	CI

Tranche Update on Qianjiang Yongan Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on April 30, 2024.

July 02, 2024 at 03:38 pm

From April 29, 2024 to June 30, 2024, the company has repurchased 1,861,050 shares, representing 0.63% for CNY 14.3 million. With this, the company has completed the repurchase of 1,861,050 shares, representing 0.63% for CNY 14.3 million under the buyback announced on April 30, 2024.

Latest news about Qianjiang Yongan Pharmaceutical Co., Ltd.

Tranche Update on Qianjiang Yongan Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on April 30, 2024.	07-02	CI
Qianjiang Yongan Pharmaceutical Co., Ltd. Approves the Final Cash Dividend on A Shares for the Year 2023, Payable on 05 July 2024	06-28	CI
Qianjiang Yongan Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 80 million worth of its shares.	04-29	CI
Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-29	CI
Qianjiang Yongan Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	04-28	CI
Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-18	CI
Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26	CI
Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-23	CI
Qianjiang Yongan Pharma Patents Purification Method For Taurine Mother Liquor in Europe, Indonesia	23-08-09	MT
Qianjiang Yongan Pharmaceutical Co., Ltd Approves Cash Dividend for the Year 2022, Payable on July 5, 2023	23-06-21	CI
Yongan Pharma Registers New Health Food Products	23-06-06	MT
Qianjiang Yongan Pharma to Buy 6.5% Stake in Local Chemical Producer For 30 Million Yuan	23-05-24	MT
Huanggang Yongan Pharmaceutical Co., Ltd. announced that it expects to receive CNY 30 million in funding from Qianjiang Yongan Pharmaceutical Co., Ltd.	23-05-22	CI
Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Qianjiang Yongan Pharmaceutical Co., Ltd. Proposes Final Dividend for the Year 2022	23-03-30	CI
Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-29	CI
Yongan Pharma Unit Gets Food Registration Certificate for Ginseng Tablets	23-01-06	MT
Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-25	CI
Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-25	CI
Qianjiang Yongan Pharma Patents Taurine, Salt Preparation in Japan	22-08-11	MT
Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-26	CI
Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-24	CI
Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-26	CI
Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-27	CI
Qianjiang Yongan Pharmaceutical Co., Ltd. Announces Final Cash Dividend for 2020, Payable on July 9, 2021	21-07-05	CI

Chart Qianjiang Yongan Pharmaceutical Co., Ltd.

Duration

Period

Chart Qianjiang Yongan Pharmaceutical Co., Ltd.

More charts

Company Profile

Qianjiang Yongan Pharmaceutical Co., Ltd. is a China-based company principally engaged in the manufacture and sales of taurine products. The Company operates through three main segments. The Taurine Products segment is mainly engaged in the research, development, manufacture and sales of taurine products, as well as the manufacture and sales of ethylene oxide. The Food Supplement segment is mainly involved in the research, development, manufacture and sales of dietary supplement, as well as the import and sales of overseas dietary supplement. The Health Field segment is mainly involved in the equity or industrial investment in health-related field.

Sector

Pharmaceuticals

Calendar

2024-08-27 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
QIANJIANG YONGAN PHARMACEUTICAL CO., LTD.	-28.02%	286M
ELI LILLY AND COMPANY	+55.35%	848B
NOVO NORDISK A/S	+31.64%	627B
JOHNSON & JOHNSON	-0.10%	363B
MERCK & CO., INC.	+15.47%	318B
ABBVIE INC.	+13.10%	299B
ASTRAZENECA PLC	+15.51%	243B
NOVARTIS AG	+16.72%	225B
AMGEN INC.	+16.54%	179B
PFIZER, INC.	+4.31%	167B

Other Pharmaceuticals

Qianjiang Yongan Pharmaceutical Co., Ltd.

Equities

002365

CNE100000LZ9

Pharmaceuticals

Tranche Update on Qianjiang Yongan Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on April 30, 2024.

Latest news about Qianjiang Yongan Pharmaceutical Co., Ltd.

Chart Qianjiang Yongan Pharmaceutical Co., Ltd.

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Other Pharmaceuticals